From Genotype to Phenotype: Through Chromatin

Advances in sequencing technologies have enabled the exploration of the genetic basis for several clinical disorders by allowing identification of causal mutations in rare genetic diseases. Sequencing technology has also facilitated genome-wide association studies to gather single nucleotide polymor...

Full description

Bibliographic Details
Main Authors: Julia Romanowska, Anagha Joshi
Format: Article
Language:English
Published: MDPI AG 2019-01-01
Series:Genes
Subjects:
Online Access:https://www.mdpi.com/2073-4425/10/2/76
id doaj-262eb1a9cabe407c91ff641f44a0c9a1
record_format Article
spelling doaj-262eb1a9cabe407c91ff641f44a0c9a12020-11-24T21:17:09ZengMDPI AGGenes2073-44252019-01-011027610.3390/genes10020076genes10020076From Genotype to Phenotype: Through ChromatinJulia Romanowska0Anagha Joshi1Department of Global Public Health and Primary Care, University of Bergen, 5018, Bergen, NorwayComputational Biology Unit, Department of Clinical Science, University of Bergen, 5021, Bergen, NorwayAdvances in sequencing technologies have enabled the exploration of the genetic basis for several clinical disorders by allowing identification of causal mutations in rare genetic diseases. Sequencing technology has also facilitated genome-wide association studies to gather single nucleotide polymorphisms in common diseases including cancer and diabetes. Sequencing has therefore become common in the clinic for both prognostics and diagnostics. The success in follow-up steps, i.e., mapping mutations to causal genes and therapeutic targets to further the development of novel therapies, has nevertheless been very limited. This is because most mutations associated with diseases lie in inter-genic regions including the so-called regulatory genome. Additionally, no genetic causes are apparent for many diseases including neurodegenerative disorders. A complementary approach is therefore gaining interest, namely to focus on <i>epigenetic</i> control of the disease to generate more complete functional genomic maps. To this end, several recent studies have generated large-scale epigenetic datasets in a disease context to form a link between genotype and phenotype. We focus DNA methylation and important histone marks, where recent advances have been made thanks to technology improvements, cost effectiveness, and large meta-scale epigenome consortia efforts. We summarize recent studies unravelling the mechanistic understanding of epigenetic processes in disease development and progression. Moreover, we show how methodology advancements enable causal relationships to be established, and we pinpoint the most important issues to be addressed by future research.https://www.mdpi.com/2073-4425/10/2/76epigeneticschromatin modificationsequencingregulatory genomicsdisease variants
collection DOAJ
language English
format Article
sources DOAJ
author Julia Romanowska
Anagha Joshi
spellingShingle Julia Romanowska
Anagha Joshi
From Genotype to Phenotype: Through Chromatin
Genes
epigenetics
chromatin modification
sequencing
regulatory genomics
disease variants
author_facet Julia Romanowska
Anagha Joshi
author_sort Julia Romanowska
title From Genotype to Phenotype: Through Chromatin
title_short From Genotype to Phenotype: Through Chromatin
title_full From Genotype to Phenotype: Through Chromatin
title_fullStr From Genotype to Phenotype: Through Chromatin
title_full_unstemmed From Genotype to Phenotype: Through Chromatin
title_sort from genotype to phenotype: through chromatin
publisher MDPI AG
series Genes
issn 2073-4425
publishDate 2019-01-01
description Advances in sequencing technologies have enabled the exploration of the genetic basis for several clinical disorders by allowing identification of causal mutations in rare genetic diseases. Sequencing technology has also facilitated genome-wide association studies to gather single nucleotide polymorphisms in common diseases including cancer and diabetes. Sequencing has therefore become common in the clinic for both prognostics and diagnostics. The success in follow-up steps, i.e., mapping mutations to causal genes and therapeutic targets to further the development of novel therapies, has nevertheless been very limited. This is because most mutations associated with diseases lie in inter-genic regions including the so-called regulatory genome. Additionally, no genetic causes are apparent for many diseases including neurodegenerative disorders. A complementary approach is therefore gaining interest, namely to focus on <i>epigenetic</i> control of the disease to generate more complete functional genomic maps. To this end, several recent studies have generated large-scale epigenetic datasets in a disease context to form a link between genotype and phenotype. We focus DNA methylation and important histone marks, where recent advances have been made thanks to technology improvements, cost effectiveness, and large meta-scale epigenome consortia efforts. We summarize recent studies unravelling the mechanistic understanding of epigenetic processes in disease development and progression. Moreover, we show how methodology advancements enable causal relationships to be established, and we pinpoint the most important issues to be addressed by future research.
topic epigenetics
chromatin modification
sequencing
regulatory genomics
disease variants
url https://www.mdpi.com/2073-4425/10/2/76
work_keys_str_mv AT juliaromanowska fromgenotypetophenotypethroughchromatin
AT anaghajoshi fromgenotypetophenotypethroughchromatin
_version_ 1726013966700773376